Objectives: Intrahepatic cholangiocarcinoma (ICC) is a rare type of liver cancer. No clinically useful prognostic factors have been reported for patients with advanced ICC. In the present study, we aimed to evaluate the clinical prognostic factors of patients with advanced ICC receiving gemcitabine plus cisplatin combination therapy (GC) as standard first-line chemotherapy. Methods: A retrospective analysis was performed of the data of patients with ICC treated at our institution from March 2011 to January 2016. We used the Cox regression model and estimated the hazard ratios of potential prognostic factors for survival. Results: Of 216 patients with biliary tract cancer receiving GC as first-line chemotherapy, we extracted data for 77 patients who were diagnosed with ICC and received GC as first-line chemotherapy. The median overall survival was 13.8 months (95% CI, 8.9-18.6). In multivariate analysis, pretreatment serum lactate dehydrogenase (hazard ratio [HR]: 2.53, p = 0.005), C-reactive protein (HR: 3.06, p = 0.001), and carcinoembryonic antigen (HR: 2.39, p = 0.03) levels were significantly associated with overall survival. Conclusions: Readily available clinical laboratory values reliably predicted the prognosis of ICC patients receiving GC therapy. If validated in other studies, these results may provide a useful tool for individual patient-risk evaluation and the design and interpretation of future trials.

Keywords:
Cholangiocarcinoma, Gemcitabine, Biliary tract cancer, Intrahepatic cholangiocarcinoma, Prognostic factors
1.
Randi G, Malvezzi M, Levi F, et al: Epidemiology of biliary tract cancers: an update. Ann Oncol 2009;20:146-159.
2.
Matsuda T, Marugame T: International comparisons of cumulative risk of gallbladder cancer and other biliary tract cancer, from Cancer Incidence in Five Continents Vol. VIII. Jpn J Clin Oncol 2007;37:74-75.
3.
de Groen PC, Gores GJ, LaRusso NF, et al: Biliary tract cancers. N Engl J Med 1999;341:1368-1378.
4.
Charbel H, Al-Kawas FH: Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis. Curr Gastroenterol Rep 2011;13:182-187.
5.
Valle J, Wasan H, Palmer DH, et al: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010;362:1273-1281.
6.
Eckel F, Schmid RM: Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007;96:896-902.
7.
Park I, Lee JL, Ryu MH, et al: Prognostic factors and predictive model in patients with advanced biliary tract adenocarcinoma receiving first-line palliative chemotherapy. Cancer 2009;115:4148-4155.
8.
Fornaro L, Cereda S, Aprile G, et al: Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer. Br J Cancer 2014;110:2165-2169.
9.
McNamara MG, Templeton AJ, Maganti M, et al: Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer. Eur J Cancer 2014;50:1581-1589.
10.
Peixoto RD, Renouf D, Lim H: A population based analysis of prognostic factors in advanced biliary tract cancer. J Gastrointest Oncol 2014;5:428-432.
11.
Everhart JE, Ruhl CE: Burden of digestive diseases in the United States part II: lower gastrointestinal diseases. Gastroenterology 2009;136:741-744.
12.
Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002;2:10.
13.
Pichlmayr R, Lamesch P, Weimann A, et al: Surgical treatment of cholangiocellular carcinoma. World J Surg 1995;19:83-88.
14.
Yamamoto J, Kosuge T, Takayama T, et al: Surgical treatment of intrahepatic cholangiocarcinoma: four patients surviving more than five years. Surgery 1992;111:617-622.
15.
Schlinkert RT, Nagorney DM, Van Heerden JA, Adson MA: Intrahepatic cholangiocarcinoma: clinical aspects, pathology and treatment. HPB Surg 1992;5:95-101; discussion 101-102.
16.
de Jong MC, Nathan H, Sotiropoulos GC, et al: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol 2011;29:3140-3145.
17.
Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-216.
18.
Furuse J, Okusaka T, Funakoshi A, et al: Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer. Jpn J Clin Oncol 2006;36:552-556.
19.
Grenader T, Waddell T, Peckitt C, et al: Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial. Ann Oncol 2016;27:687-692.
20.
Valle JW, Furuse J, Jitlal M, et al: Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Ann Oncol 2014;25:391-398.
21.
Blechacz BG, Gores GJ: Tumors of the bile ducts, gallbladder, and ampulla. In: Feldman (ed): Sleisenger and Fordtran's Gastrointestinal and Liver Disease, vol 1, ed 9. Philadelphia, Saunders, 2010, pp 1171-1176.
22.
Jaiswal M, LaRusso NF, Burgart LJ, Gores GJ: Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res 2000;60:184-190.
23.
Proctor MJ, Talwar D, Balmar SM, et al: The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 2010;103:870-876.
24.
Faloppi L, Del Prete M, Casadei Garnidi A, et al: The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy. Sci Rep 2016;6:24136.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.